Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial (Q44158735)

30 November 2017

Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial (English)

1 reference

30 November 2017

1 reference

pulmonary hypertension

1 reference

1

1 reference

30 November 2017

9

1 reference

30 November 2017

10

1 reference

30 November 2017

Horst Olschewski

5

0 references

Norbert Weissmann

object named as

Norbert Weissmann

6

0 references

Ralph T Schermuly

object named as

Ralph T Schermuly

4

0 references

Ralph Wiedemann

2

object named as

Ralph Wiedemann

1 reference

30 November 2017

8

Dieter Walmrath

1 reference

30 November 2017

Frank Rose

3

1 reference

PubMed ID

12354470

30 November 2017

Andreas Gunther

7

1 reference

PubMed ID

12354470

30 November 2017

language of work or name

English

0 references

publication date

1 September 2002

1 reference

30 November 2017

1 reference

30 November 2017

360

1 reference

30 November 2017

895-900

1 reference

30 November 2017

9337

1 reference

Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model

30 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911024-5

7 January 2021

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911024-5

7 January 2021

New treatments for pulmonary fibrosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911024-5

7 January 2021

Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911024-5

7 January 2021

Inhaled nitric oxide for the adult respiratory distress syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911024-5

7 January 2021

Aerosolised prostacyclin in adult respiratory distress syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911024-5

7 January 2021

Aerosolized Prostacyclin and Iloprost in Severe Pulmonary Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911024-5

7 January 2021

Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911024-5

7 January 2021

Long-Term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin Analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911024-5

7 January 2021

Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911024-5

7 January 2021

American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911024-5

7 January 2021

Conebulization of surfactant and urokinase restores gas exchange in perfused lungs with alveolar fibrin formation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911024-5

7 January 2021

A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911024-5

7 January 2021

Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911024-5

7 January 2021

Ca/CaM-stimulated and cGMP-specific phosphodiesterases in vascular and non-vascular tissues.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911024-5

7 January 2021

Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911024-5

7 January 2021

Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911024-5

7 January 2021

Atrial natriuretic peptide in severe primary and nonprimary pulmonary hypertension: response to iloprost inhalation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911024-5

7 January 2021

Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911024-5

7 January 2021

Nitric oxide generation and hypoxic vasoconstriction in buffer-perfused rabbit lungs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911024-5

7 January 2021

NO and reactive oxygen species are involved in biphasic hypoxic vasoconstriction of isolated rabbit lungs.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911024-5

7 January 2021

Regulation of pulmonary circulation by alveolar oxygen tension via airway nitric oxide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911024-5

7 January 2021

10.1016/S0140-6736(02)11024-5

Identifiers

DOI

1 reference

30 November 2017

1 reference

PubMed ID

12354470